Introduction
Some research peptides are interesting precisely because they refuse to belong to a single discipline. Selank — the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — is one of them. Its design starts not from a neurotransmitter system but from the immune system: it is built on tuftsin, an endogenous tetrapeptide released from immunoglobulin G and long characterized as an immunomodulatory regulatory peptide. Selank inherits that immunomodulatory character and is then studied in the central nervous system, placing it squarely at what the literature describes as the neuropeptide-immune interface (Kolomin et al., 2013). This article is an overview of Selank at that interface. It describes the peptide's tuftsin lineage, the immunomodulatory character it inherits, and the biochemical readout the literature emphasizes most clearly in this context — effects on enkephalin metabolism, where Selank is described as slowing the enzymatic breakdown of endogenous enkephalins. Everything here is framed strictly for laboratory research use only. The observations are preclinical and in-vitro readouts from the peer-reviewed regulatory-peptide literature — not human outcomes, and nothing here describes, recommends, or implies any human use.Mechanism of Action
The neuropeptide-immune interface is a real and well-studied region of biology: signaling molecules originally identified in immune contexts also act in the nervous system, and vice versa. Tuftsin sits in exactly this territory. As a fragment of immunoglobulin G, it is immunological by origin, yet its regulatory activity has long been studied in neural contexts as well. Selank, by preserving the complete tuftsin recognition core (Thr-Lys-Pro-Arg) within its stabilized heptapeptide structure, carries that dual character forward — it is the synthetic descendant of an immunomodulatory peptide, studied as a regulatory neuropeptide (Kolomin et al., 2013). The biochemical readout the literature emphasizes at this interface is enkephalin metabolism. Enkephalins are endogenous opioid peptides whose duration of action is governed by the enzymes that degrade them — principally peptidases that cleave the enkephalin sequence. The regulatory-peptide literature describes Selank as affecting enkephalin metabolism by slowing this enzymatic breakdown, a biochemical readout linked to its tuftsin lineage and to its activity at the neuropeptide-immune interface in research models (Kolomin et al., 2013). Slowing degradation of an endogenous peptide is a metabolic mechanism — an effect on how long the native molecule persists — rather than a direct action on a single receptor, and it is studied as such. Around this central readout, the literature also situates Selank among the tuftsin-derived regulators that have been examined for effects on neuro-immune signaling and neurotrophic-factor expression (Volkova et al., 2016). The unifying frame for this overview is the interface itself: an immunomodulatory parent, a neural research context, and a metabolic readout that connects the two.Mechanism of Action — Deep Dive
Inheriting tuftsin's immunomodulatory character. Because Selank preserves the intact tuftsin core, it inherits the immunomodulatory identity that has been ascribed to its parent in the regulatory-peptide literature. This is what justifies studying Selank at the neuropeptide-immune interface rather than treating it as a purely neural compound: its lineage places it there by construction (Kolomin et al., 2013). For a researcher, that lineage is a starting hypothesis — the parent's documented immune activity directs attention toward neuro-immune readouts in the analog. Enkephalin metabolism as a peptidase-level readout. The most concretely described biochemical effect at this interface is on enkephalin metabolism. Enkephalins are short opioid peptides cleaved by peptidases; the rate of that cleavage sets how long the endogenous signal persists. Describing Selank as slowing enkephalin breakdown is therefore a statement about enzymatic metabolism — about the durability of an endogenous peptide pool — rather than about direct receptor agonism (Kolomin et al., 2013). This is a meaningful mechanistic distinction: it locates the readout at the level of peptide turnover, which is a different experimental target from receptor binding. A multi-readout interface. The neuropeptide-immune interface is not a single measurement. Alongside enkephalin metabolism, the broader literature on tuftsin-derived regulators describes neuro-immune signaling and neurotrophic-factor expression as part of the same regional picture (Volkova et al., 2016). For experimental design, that breadth means the interface must be probed with multiple, complementary readouts — enzymatic, signaling, and transcriptional — rather than a single assay, because no one measurement captures the full character a tuftsin-lineage peptide brings to this region. Why the lineage frames the mechanism. The thread running through all of this is the tuftsin origin. The immunomodulatory parent supplies the rationale for studying immune-adjacent readouts; the preserved core supplies the structural continuity; and the enkephalin-metabolism finding supplies a concrete biochemical anchor. Taken together they make Selank coherent as an object of neuro-immune research rather than a collection of unrelated observations.Key Research Findings
The findings below are preclinical and in-vitro observations from the peer-reviewed regulatory-peptide literature — not human outcomes and not human-use guidance.Finding 1 — Enkephalin-metabolism modulation
Type of evidence: biochemical characterization in the regulatory-peptide literature (Kolomin et al., 2013). Method context: description of Selank's effect on the enzymatic degradation of endogenous enkephalins in research models. Finding: Selank is described as affecting enkephalin metabolism by slowing the enzymatic breakdown of endogenous enkephalins. Why it matters: it identifies a peptidase-level metabolic readout — an effect on endogenous-peptide turnover — distinct from direct receptor agonism (Kolomin et al., 2013).Finding 2 — Inherited tuftsin immunomodulatory lineage
Type of evidence: structural/lineage characterization (Kolomin et al., 2013). Method context: description of Selank as a synthetic analog preserving the immunomodulatory tuftsin core. Finding: Selank inherits the immunomodulatory character of its tuftsin parent, situating it at the neuropeptide-immune interface. Why it matters: the lineage provides the rationale for studying immune-adjacent readouts in a compound otherwise examined as a regulatory neuropeptide (Kolomin et al., 2013).Finding 3 — A multi-readout neuro-immune profile
Type of evidence: in-vivo and review-level characterization (Volkova et al., 2016; Kolomin et al., 2013). Method context: synthesis of preclinical readouts spanning neuro-immune signaling and neurotrophic-factor expression for tuftsin-derived regulators. Finding: the neuropeptide-immune interface around Selank is described through multiple complementary readouts rather than a single measurement. Why it matters: it establishes that probing this interface requires several assay types and shapes how research designs are constructed (Volkova et al., 2016).Related Compounds Comparison Table
This comparison is descriptive biochemistry intended to orient research design; none of these molecules is presented for any human use.| Molecule | Class | Neuro-immune relationship | Relationship to Selank |
|---|---|---|---|
| Selank | Synthetic tuftsin-analog heptapeptide | Studied at the neuropeptide-immune interface; affects enkephalin metabolism | The reference molecule (this article) |
| Tuftsin | Endogenous immunomodulatory tetrapeptide | The immunomodulatory parent; recognition core | Selank's structural and immunological origin |
| Enkephalins | Endogenous opioid peptides | Substrates whose enzymatic breakdown Selank is described as slowing | The endogenous pool implicated in the metabolic readout |
Research Applications
Within laboratory settings, research-grade Selank is studied as a reference compound for neuropeptide-immune interface research, as a defined input for investigations of enkephalin metabolism and endogenous-peptide turnover in preclinical models, and as a representative tuftsin-lineage regulator for probing how an immunomodulatory parent's character carries into a synthetic neural analog. It functions as a characterized tool compound for relating peptidase-level metabolic readouts to broader neuro-immune signaling in research systems. Across these applications, Selank serves as a defined reference for neuro-immune research — never as a product intended for application outside the laboratory.Storage & Handling Protocols for Research Use
Research-grade Selank is typically supplied as a lyophilized peptide powder, a format chosen because dry material is markedly more stable than material in solution. The considerations below are general laboratory-storage practice and are not instructions for any human use. Dry powder is commonly stored at −20 °C or colder, with many laboratories using −80 °C for archival material, the vial protected from moisture by desiccant and shielded from light. Because the powder is hygroscopic, laboratories typically allow a sealed vial to equilibrate to room temperature before opening. Material brought into solution is far less stable than the dry form — prone to aggregation, surface adsorption, and hydrolysis, with stability sensitive to pH, temperature, and freeze–thaw cycling — so many groups prepare small single-use aliquots rather than repeatedly thawing one tube. Because no generic shelf life can be assumed across every laboratory's conditions, research groups validate stability empirically. VOREX does not provide reconstitution recipes, concentrations, or use protocols; those decisions sit with the qualified researcher.Laboratory Handling & Best Practices
Sound handling of a research reference peptide is largely about traceability and documentation. Record the vial's lot number against every experiment, and have any working aliquot inherit the parent lot identifier.Use clean glassware and appropriate personal protective equipment, document storage history and freeze–thaw count, and weigh small quantities on a calibrated analytical balance, accounting for the hygroscopic tendency of lyophilized powders. None of these practices involves dosing, route of administration, or human-use preparation; they exist to protect data integrity and reproducibility.What the Research Doesn't Tell Us
The literature is candid about the limits of this neuro-immune work. A description of slowed enkephalin metabolism characterizes an effect on endogenous-peptide turnover in research models; it does not, on its own, map the full set of peptidases involved or the downstream consequences of altered turnover in an intact organism. Inheriting tuftsin's immunomodulatory lineage provides a rationale for studying immune-adjacent readouts but does not by itself enumerate every neuro-immune pathway Selank engages — that requires deliberate, system-specific study. And the interface is intrinsically multi-dimensional, so any single readout is necessarily partial. For the researcher, the value of Selank here is precisely its well-defined tuftsin lineage and its concrete enkephalin-metabolism readout — reliable anchors against which more specific neuro-immune questions can be asked.Conclusion
Selank, examined at the neuropeptide-immune interface, is a synthetic tuftsin-analog heptapeptide that inherits its parent's immunomodulatory character and is described in the literature as slowing the enzymatic breakdown of endogenous enkephalins. That enkephalin-metabolism readout gives the interface a concrete biochemical anchor, and the tuftsin lineage gives the whole picture a coherent origin spanning immune and neural research. It is an interface worth characterizing rather than a claim worth selling — a defined tool compound for laboratories studying neuro-immune regulatory peptides. View research data · Request COA · Explore mechanism studiesReferences
- Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., & Myasoedov, N. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine, 4(4), 223–252. https://doi.org/10.4236/nm.2013.44035
- Volkova, A., Bondarenko, E., Pchelintseva, E., et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7, 31. https://pubmed.ncbi.nlm.nih.gov/26941642/
For laboratory and research use only (RUO). Not for human consumption, diagnostic, or therapeutic use. VOREX products are intended exclusively for in vitro research conducted by qualified professionals. Statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
